Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) EBT Margin (2016 - 2025)

Historic EBT Margin for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to 123.42%.

  • Enanta Pharmaceuticals' EBT Margin rose 763800.0% to 123.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 127.9%, marking a year-over-year increase of 462500.0%. This contributed to the annual value of 127.9% for FY2025, which is 462500.0% up from last year.
  • Enanta Pharmaceuticals' EBT Margin amounted to 123.42% in Q3 2025, which was up 763800.0% from 99.52% recorded in Q2 2025.
  • Enanta Pharmaceuticals' EBT Margin's 5-year high stood at 99.52% during Q2 2025, with a 5-year trough of 211.37% in Q1 2023.
  • Its 5-year average for EBT Margin is 153.59%, with a median of 154.5% in 2021.
  • Per our database at Business Quant, Enanta Pharmaceuticals' EBT Margin tumbled by -1088800bps in 2021 and then surged by 763800bps in 2025.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' EBT Margin stood at 109.05% in 2021, then fell by -13bps to 123.04% in 2022, then crashed by -54bps to 189.02% in 2023, then increased by 29bps to 133.89% in 2024, then grew by 8bps to 123.42% in 2025.
  • Its EBT Margin was 123.42% in Q3 2025, compared to 99.52% in Q2 2025 and 160.45% in Q1 2025.